Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acquisition will contribute to the expansion of export possibilities of brands such as Equazen eye q, Perskindol and Otalgan
Subscribe to our email newsletter
Swiss pharmaceutical and retail company Galenica has acquired the entirety of OM PHARMA, a biotechnology and pharmaceutical Swiss company.
Acquisition is expected to increase Galenica’s internationalisation by contributing to the expansion of export possibilities of brands such as Equazen eye q, Perskindol and Otalgan. OM PHARMA products support the existing Galenica’s portfolio with therapeutic areas and optimise risk diversification in the Vifor Pharma business sector, the company reported.
The company said, Christophe Ricard, president since 1995, will retire and the existing management team will continue under the management of Gianni Zampieri, head of industrial operations of Vifor Pharma and member of the corporate executive committee of the Galenica Group.
OM PHARMA will be managed as a profit center of Vifor Pharma. The acquisition will be accretive for the Galenica Group results already in 2009.